213 related articles for article (PubMed ID: 17341858)
1. PsoReg--the Swedish registry for systemic psoriasis treatment. The registry's design and objectives.
Schmitt-Egenolf M
Dermatology; 2007; 214(2):112-7. PubMed ID: 17341858
[TBL] [Abstract][Full Text] [Related]
2. Psoriasis therapy in real life: the need for registries.
Schmitt-Egenolf M
Dermatology; 2006; 213(4):327-30. PubMed ID: 17135739
[TBL] [Abstract][Full Text] [Related]
3. National registries of systemic treatment for psoriasis and the European 'Psonet' initiative.
Lecluse LL; Naldi L; Stern RS; Spuls PI
Dermatology; 2009; 218(4):347-56. PubMed ID: 19077384
[TBL] [Abstract][Full Text] [Related]
4. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
5. Decision points for the initiation of systemic treatment for psoriasis.
Feldman SR; Koo JY; Menter A; Bagel J
J Am Acad Dermatol; 2005 Jul; 53(1):101-7. PubMed ID: 15965429
[TBL] [Abstract][Full Text] [Related]
6. Adverse events from systemic therapies for psoriasis are common in clinical practice.
Pearce DJ; Higgins KB; Stealey KH; Balkrishnan R; Crane MM; Camacho F; Fleischer AB; Feldman SR
J Dermatolog Treat; 2006; 17(5):288-93. PubMed ID: 17092859
[TBL] [Abstract][Full Text] [Related]
7. Systemic and light therapies for the management of childhood psoriasis: part II.
Cordoro KM
Skin Therapy Lett; 2008 May; 13(4):1-3. PubMed ID: 18648714
[TBL] [Abstract][Full Text] [Related]
8. Care of patients with psoriasis: an audit of U.K. services in secondary care.
Eedy DJ; Griffiths CE; Chalmers RJ; Ormerod AD; Smith CH; Barker JN; Potter J; Ingham J; Lowe D; Burge S
Br J Dermatol; 2009 Mar; 160(3):557-64. PubMed ID: 19120330
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis of the face and flexures.
van de Kerkhof PC; Murphy GM; Austad J; Ljungberg A; Cambazard F; Duvold LB
J Dermatolog Treat; 2007; 18(6):351-60. PubMed ID: 17907013
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS
Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804
[TBL] [Abstract][Full Text] [Related]
13. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis.
Ozdemir M; Engin B; Baysal I; Mevlitoğlu I
Acta Derm Venereol; 2008; 88(6):589-93. PubMed ID: 19002344
[TBL] [Abstract][Full Text] [Related]
14. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting.
de Korte J; van der Valk PG; Sprangers MA; Damstra RJ; Kunkeler AC; Lijnen RL; Oranje AP; de Rie MA; de Waard-van der Spek FB; Hol CW; van de Kerkhof PC
Br J Dermatol; 2008 Feb; 158(2):375-81. PubMed ID: 18067483
[TBL] [Abstract][Full Text] [Related]
15. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.
Opmeer BC; Heydendael VM; deBorgie CA; Spuls PI; Bossuyt PM; Bos JD; de Rie MA
J Clin Epidemiol; 2007 Jul; 60(7):696-703. PubMed ID: 17573985
[TBL] [Abstract][Full Text] [Related]
16. [Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].
Puig L; Bordas X; Carrascosa JM; Daudén E; Ferrándiz C; Hernanz JM; López-Estebaranz JL; Moreno JC; Sánchez-Carazo JL; Vanaclocha F; Vázquez-Veiga H;
Actas Dermosifiliogr; 2009 May; 100(4):277-86. PubMed ID: 19463230
[TBL] [Abstract][Full Text] [Related]
17. [Data sources for continual quality improvement in medical rehabilitation- the QS-Reha procedure of the statutory health insurance funds and the Eva-Reha documentation system of MDK Rhineland-palatinate].
Bassler M; Nosper M; Follert P; Böwering L; Polak U
Rehabilitation (Stuttg); 2007 Jun; 46(3):155-63. PubMed ID: 17582556
[TBL] [Abstract][Full Text] [Related]
18. Treatment goals in psoriasis.
Reich K; Mrowietz U
J Dtsch Dermatol Ges; 2007 Jul; 5(7):566-74. PubMed ID: 17610606
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis.
Blake J
Prof Nurse; 2002 Nov; 18(3):133-4. PubMed ID: 12465536
[TBL] [Abstract][Full Text] [Related]
20. Topical therapy for the management of childhood psoriasis: part I.
Cordoro KM
Skin Therapy Lett; 2008 Apr; 13(3):1-3. PubMed ID: 18506356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
